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Abstract When planning ageing research using rodent
models, the logistics of supply, long term housing and
infrastructure provision are important factors to take into
consideration. These issues need to be prioritised to ensure
they meet the requirements of experiments which poten-
tially will not be completed for several years. Although
these issues are not unique to this discipline, the longevity
of experiments and indeed the animals, requires a high
level of consistency and sustainability to be maintained
throughout lengthy periods of time. Moreover, the need to
access aged stock or material for more immediate experi-
ments poses many issues for the completion of pilot studies
and/or short term intervention studies on older models. In
this article, we highlight the increasing demand for ageing
research, the resources and infrastructure involved, and the
need for large-scale collaborative programmes to advance
studies in both a timely and a cost-effective way.
Introduction
Research using rodents as mammalian models for studying
ageing are yielding considerable information on the genetic
influences on longevity and, more recently, on the value of
interventions targeting mechanisms of ageing to delay
onset of age-related diseases (Check Hayden 2015; Kirk-
land 2013; Yuan et al. 2011). Until now, research on ageing
and age-related diseases was considered separate fields of
investigation with most research on ageing focusing on
identifying influences on longevity, and research on age-
related diseases centring on the study of mechanisms and
treatment of a single disease. Often, mechanistic studies of
diseases have been performed in young rodents and the
effect of age on the disease pathogenesis or responses to
interventions have not been considered. However, it is now
clear that these approaches are far removed from the
problems they are trying to solve. Age is the single largest
risk factor for strokes, cardiovascular diseases, cancers,
diabetes, and most other chronic diseases. In addition,
approximately 60 % of those over 65 have been shown to
have more than one condition at the same time, termed
multimorbidity (Vogeli et al. 2007), and this is the main
factor responsible for the decreased quality of life and
increased health-care costs. Indeed, over 80 % of Medicare
costs are related to age-related multimorbidity (Wolff et al.
2002). These patients often show decreased resilience and
respond not so well to treatment. In addition, they show an
increase in risk of serious side effects associated with
polypharmacy (Marengoni et al. 2014; Tinetti et al. 2004).
For these reasons, the Population Level Commissioning for
the Future report from the UK government has recom-
mended a more holistic approach to the care of age-related
diseases, which moves away from the single disease
approach (http://www.nhsiq.nhs.uk/news-events/news/
population-level-commissioning-for-the-future.aspx).
With this in mind, scientists and geriatricians have
proposed targeting research to the discovery of interven-
tions which target common mechanisms of ageing to delay
the onset of more than one age-related disease at the same
time and improve health. This is based on evidence in
preclinical murine models. Administration of interventions,
such as dietary restriction (Fontana and Partridge 2015),
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rapamycin (Kaeberlein 2014), mefortmin (Pryor and Cab-
reiro 2015) or molecules which eliminate senescence cells
(Chang et al. 2016; Zhu et al. 2015), has resulted in the
delay of multiple age-related tissue dysfunction with
improved cardiac function, cataracts, insulin sensitivity and
reduced incidence of cancer. This suggests that delaying
the onset of multimorbidity with a single agent may be
achievable. However, the ability to conduct such preclini-
cal intervention testing studies, which are scientifically
robust and use suitable murine models and endpoints that
are relevant to clinical translation not only poses technical
challenges but also requires resources and interdisciplinary
expertise.
In this article, we explore these challenges and propose
that appropriate specialised infrastructures may be required
to fast track those studies and reduce costs, both financial
and in terms of animal usage.
Models
The choice of animal models, which reproduce aspects of
multimorbidity, frailty or loss of resilience and in which to
accurately assess the effects of genes or molecules on
healthspan, is still the subject of debate in the ageing
research community. At present, the common practice is
either to extrapolate data obtained from interventions in
genetically homogeneous animal models or in disease
models that develop the condition early in life. Yet, human
populations are genetically heterogeneous and nearly all
chronic diseases develop in humans over time and manifest
later in life. In addition, no single cause is responsible for
more than 25–30 % of human mortality. In contrast, in
C57BL/6, the most common strain of mouse used for
preclinical testing and to derive mutant mice at present,
86–89 % die of cancer (Blackwell et al. 1995). For com-
parison, cancer accounts for 23 % of the deaths in many
developed countries (National Vital Statistics Report
2005).
In the USA, the intervention testing programme (ITP) at
the NationaI Institute of Aging (NIA) has decided to use a
four-way cross of different inbred mouse strains to increase
genetic diversity. Whilst these mice have demonstrated a
wider variety of conditions at death than C57BL/6, they are
still far from the diverse disease phenotypes seen in
humans (Nadon et al. 2008). Disease models often develop
the condition early in life and spontaneously, in contrast to
humans in whom nearly all chronic diseases develop over
time and manifest in later life. Determining whether an
intervention alters the onset of a disease in older mice is a
complex task. This may require the introduction of a
mutation which makes it susceptible to a disease. This is
usually best achieved by generating conditional knock outs,
which allow the manipulation of the onset of disease later
in life. However, there are a limited number of such
transgenic lines. The International Mouse Phenotyping
Consortium (IMPC), aims to generate mouse lines and
phenotypic analysis of knock out mouse mutants as models
of disease (Brown and Moore 2012), but there has been
little or no work to test the effect of age on disease
development or the susceptibility of developing a second
disease following the onset of the initial illness. Therefore,
there is a real need to develop and properly characterise
genetically modified animal models susceptible to multiple
organ dysfunctions and chronic, later-onset diseases which
can be challenged with stressors to test their resilience.
This needs to be done using a standardised phenotypic
pipeline of measurements, repeated over time in longitu-
dinal studies. More importantly, it is unlikely that one
model will recapitulate enough features of age-related
multimorbidity or frailty to generate robust results to sup-
port clinical translation, and multiple models may be
required. Testing in multiple models is resource intense and
requires infrastructure with large capabilities.
Reproducibility: strain, genetic integrity,
environmental control and experimental design
There has been much publicity around the seemingly
unreproducible data from animal studies. Undoubtedly the
source of the lack of robustness in some rodent models is
complex and multifactorial. However, there are emerging
themes of strain, sex, genetic quality, environmental con-
trol and experimental design which are becoming even
more pertinent when considering a study lasting over
2 years, with large investments in terms of both animal
numbers and costs (Reardon 2016). Strain and sex are a
source of great variability in outcomes in longevity studies.
The introduction of 40 % dietary restriction to 41 different
inbred strains of mice resulted in the predicted extension of
lifespan in only 5 % of the strains in male and 21 % in
female. Dietary restriction either had no effect or shortened
lifespan in the other strains when compared to their
respective ad libitum-fed littermates (Liao et al. 2010).
Extensive single nucleotide polymorphism (SNP) panels
now enables more quality assurance of mouse strains than
ever before as well as the opportunity to genetically screen
stocks prior to their entry into ageing studies. Most mouse
suppliers run genetic quality control programs to prevent
gross contamination from other strains and limit the
inevitable genetic drift. It is therefore relatively easy to
access wild type mice of a high genetic integrity and
importantly, of known genotype. The increasing wealth of
phenotype data also makes it possible to exclude strains
which carry mutations which may confound experimental
data, such as C57BL/6 strains for hearing research as a
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mutation in cadherin 23 renders them deaf as they mature
(Kane et al. 2012).
Controlling the genetic background of experimental
cohorts with complex allele combinations is, however,
more difficult. Intercrossing two strains of different genetic
backgrounds will result in novel and different combina-
tions of genes likely to modulate the effects of any genetic
alterations to be studied. The challenge of ageing condi-
tional transgenic models, with the prospect of lines bearing
recombinase transgenes on different backgrounds than the
conditionally engineered genes, poses issues not only in
appropriate control cohorts but also in welfare and phe-
notypic issues of previously uncharacterised mixed genetic
backgrounds. The generation of new mouse lines on
genetically controlled coisogenic backgrounds using new
genome editing techniques will inevitably reduce the
variation caused by undefined background effects.
It is an obvious assumption that changes in environment
over an extended period of housing has the potential to
affect phenotypes and responses to intervention studies. A
few decades ago it would have been predicted that this was
limited to the composition of food and general environ-
mental factors, such as temperature and humidity. How-
ever, extensive studies of how laboratory rodents are
housed and the effect of differing conditions on phenotypes
over the last few years have clarified a plethora of further
considerations. Caging, environmental enrichment, feed,
light intensity and housing density are all key factors which
research facilities strive to keep constant (Tucci et al.
2006). It is the sustainability of a constant environment
which is imperative to control ageing stock. This is not a
trivial issue, and although changes such as altering the
caging type within a facility happen infrequently which are
usually accompanied by an extensive planning exercise,
smaller changes such as the use of alternate environmental
enrichment or food supplements needs to be fastidiously
controlled. To facilitate constant and uncompromised
conditions for ageing research, it is ideal to have dedicated
colonies/rooms or facilities which are specifically designed
for sustained, constant, environmental conditions and
where the smallest of alterations in the housing of ageing
stock is discussed widely, recorded comprehensively and
the impact of which is assessed extensively. The difficulties
of accounting for all of these variables is exemplified by
the experience of the National Institute of Health (NIH)
which has recognised the importance of reaching consensus
on these practises and has established a centralised inter-
vention testing programme (NIA ITP). Despite standardi-
sation of some of these variables, testing of aspirin,
nitroflurbiprofen (NFP), 4-OH-alpha-phenyl-N-tert-butyl
nitrone (4-OH-PBN), or nordihydroguaiaretic acid
(NDGA) resulted in large variability in survival (Strong
et al. 2008). Among the possible causes was the type of
food used for the breeding stock or for weaning the mice
prior to the start of the intervention.
High mortality rates from infections, such as mouse
norovirus (Kastenmayer et al. 2008) or intermittent infec-
tions of diseases which are likely to alter immune status,
can greatly confound the analysis of the effect of genetic
alterations or interventions on mouse healthspan. The
aspiration for most modern animal facilities is for specific
pathogen free (SPF) status achieved by regular negative
test results for a list of pathogens recommended by
organisations such as FELASA (Mahler Convenor et al.
2014). The microbiological status of animals entering,
during and indeed completing ageing research programs
are important metadata to be collected through rigorous
screening and used in subsequent analysis.
Measuring healthspan
Although lifespan is a more commonly used endpoint,
healthspan is much more desirable from a clinical per-
spective. However, healthspan is more difficult to assess
and requires well equipped infrastructures with multidis-
ciplinary expertise. A number of healthspan measures have
emerged to assess the state of multiple organs, physiolog-
ical systems and behaviour in mice. Measures of physical
performance, cognitive function, body composition,
immune function, sensory acuity, and metabolic state have
been proposed as they are clinically relevant and capture
important aspects of ageing. The International Mouse
Phenotyping Consortium has published a database of
standard operating procedures that can be used to pheno-
type a mouse (www.mousephenotype.org). This has been
used mainly to phenotype young mice but it is an excellent
starting point for discussion on which tests best measure
healthspan across systems and ages and reflect clinical
outcomes. Investigators from a number of US institutions
came together to discuss what is the best way of assessing
health and their recommendation can be found in
Richardson et al. (2016) where strength and limitations of
current pipelines for the measurement of healthspan are
highlighted. Resilience in older age, defined as the ability
to better cope with adversity, is also considered a measure
of health. A number of clinically relevant perturbations and
insults to model stressors have been proposed (i.e.
chemotherapy, anaesthesia, pneumonia, hip fracture, sur-
gery, sepsis, hypovolemia, cold exposure and wound
healing), together with the rate of recovery and tolerance to
the perturbation assessed by measures such as food intake,
body weight, grooming, habitual physical activity or other
physiological variables. However, these tests present con-
siderable welfare issues, particularly in older mice and
therefore at present few centres have the capability to
introduce them and they remain largely untested. In
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addition there is a need to agree whether all these mea-
surements are better performed in longitudinal study to
comprehensively assess the natural history of changes in
measures of healthspan. Understanding the onset, order,
rate and magnitude of changes in parameters of healthspan
may foster better design, execution and interpretation of
studies of geroprotectors.
Going forward
The cost and capability to perform long-term genetic,
mechanistic and intervention studies using statistically
significant number of animals followed for long periods of
time (24–30 months) assessed by multiple tests is high.
According to power calculations executed by the NIA ITP,
each intervention should be tested in 44 male and 36
female mice, and this should be repeated in at least three
independent sites (Nadon et al. 2008). This type of
approach focuses only on lifespan as an endpoint. If
healthspan needs to be used, this will require monitoring of
a very high number of parameters, the responses to chal-
lenges in more than one strain or disease model or in
modified conditions to mimic exposure to factors such as
tobacco or alcohol, excess nutrients. This will increase the
number of animals, technology and infrastructure required.
Many research laboratories do not have the resources,
equipment or the expertise to conduct scientifically robust
intervention studies of this kind on their own. Moreover,
scientists tend to have a single discipline approach whereas
these type of approaches require multidisciplinary exper-
tise. Considering the costs for the necessary instrumenta-
tion to perform many of the measures required, the
personnel and organisational infrastructure and wide-
ranging expertise required, the possibility of creating cen-
tralised testing facilities, would make economic sense.
Centralisation would help avoid duplication and ensure
testing is rigorous and comparable across laboratories,
according to a well-established pipeline, which would
promote fast translation to the clinic. This would also allow
better planning for the acquisition of older animals for the
testing programme and donation of unused tissues for
mechanistic studies or more specialised assessment outside
the pipeline. Stocks of young wild rodents are easily pur-
chased from commercial breeders while more complex
genetically modified strains are accessible from interna-
tional repositories through the International Mouse Strain
Resource (IMSR: www.findmice.org). In both cases the
starting material of live animals or germplasm are readily
available for experiments. However, for studies requiring
aged tissue, sometimes into the geriatric range of over
2 years, there are limited supplies from commercial
breeders. This is understandable for both ethical and cost
reasons. It would not be morally acceptable to maintain
animals in laboratories ‘just in case’ they were required.
Furthermore, matching supply and demand in fast moving
academic fields is difficult and each mouse of this age
typically costs in the region of several hundreds of pounds
to house to over 2 years. Solutions to these issues must lie
in large collaborative exercises, where aged stocks can be
utilised in the most comprehensive way possible, serving a
number of research projects whilst sharing ageing resour-
ces. While in the USA the NIH has been promoting this for
some time with the NIA ITP and the Aged Rodent Tissue
bank, such infrastructures are in their infancy in Europe.
An example is the Shared Ageing Research Models (www.
Sharmuk.org), which has developed a tissue bank for the
collection of unused tissues from investigators willing to
donate the tissues and a database of live ageing colonies of
mice made available from investigators who use only one
or two tissues and are willing to donate the remaining
tissues to interested investigators for their bespoke collec-
tion. This is encouraging but more is required if we are to
meet the societal challenge of an increasing ageing
population.
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